The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
A patient is said to be in ‘remission’ once there are no detectable leukemia cells in the blood and bone marrow and when blood cells are returning to normal levels. Around 2 in 3 patients with AML achieve complete remission after their initial treatment, which is a sign that that the therapy has been effective in killing the abnormal cells.
However, low levels of cancer cells can go undetected while patients are in remission, making it important to continue with treatment as advised by your leukemia specialist. While in remission, it is also essential that patients remain under close observation and attend regular follow-ups, so that if AML returns, it is detected early. Read more about AML relapse here.
American Cancer Society. Treatment Response Rates for Acute Myeloid Leukemia (AML). https://www.cancer.org/cancer/acute-myeloid-leukemia/treating/response-rates. Accessed Jan 5, 2021.